Our group is deeply interested in understanding "how healthy and diseased lungs respond to various perturbations" at the molecular and cellular levels, and ultimately translating these insights into clinical practice. 

To achieve this, we
(1) actively develop disease modeling tools and fine-tune them to address clinically relevant questions,
(2) manipulate these models at the molecular or genomic level, and
(3) evaluate changes using cutting-edge genomic tools.